SCHEMBL4745238

SCHEMBL4745238

CN(C(=O)OC(C)(C)C)C(CO[Si](C)(C)C(C)(C)C)C(=O)O

nearest known ligand 0.34

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 1/20 0.34
AAK1 Q2M2I8 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30334661 1.00 MMP13 (0.34) MMP13AAK1
SCHEMBL30731713 1.00 MMP13 (0.34) MMP13AAK1
SCHEMBL2479842 0.88 MMP13 (0.32) MMP13
SCHEMBL3741246 0.83 AAK1 (0.31) MMP13AAK1
SCHEMBL3740151 0.82 MMP13 (0.41) MMP13AAK1
SCHEMBL4837235 0.82 AAK1 (0.31) AAK1
SCHEMBL4837241 0.82 AAK1 (0.31) AAK1
SCHEMBL31013804 0.80 PGD (0.31)
SCHEMBL25185703 0.80 MMP13 (0.38) MMP13AAK1
SCHEMBL28922954 0.80 MMP13 (0.38) MMP13AAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12384797-B2 Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia PTC THERAPEUTICS, INC. (US) 2025-08-12 US disclosed
WO-2025137639-A1 MIXED SEROTONIN RECEPTOR BINDERS FOR TREATMENT OF PSYCHOTIC DISORDERS DELIX THERAPEUTICS, INC. (US) 2025-06-26 WO disclosed
CN-117015537-A Heteroaryl aminopropanol derivatives as inhibitors of LTA4H 诺华股份有限公司 2023-11-07 CN disclosed
US-20230101747-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRÖDINGER, INC. 2023-03-30 US disclosed
US-20230057568-A1 COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA PTC THERAPEUTICS, INC. (US) 2023-02-23 US disclosed
EP-4072677-A1 COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA PTC Therapeutics, Inc. (US) 2022-10-19 EP disclosed
EP-4069369-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME Schrödinger, Inc. (US) 2022-10-12 EP disclosed
US-20220135586-A1 THIOENO[3,2-B] PYRIDIN-7-AMINE COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA PTC THERAPEUTICS, INC. (US) 2022-05-05 US disclosed
CN-113795304-A Thieno [3,2-B ] pyridin-7-amine compounds for the treatment of familial autonomic nervous dysfunction PTC医疗公司 2021-12-14 CN disclosed
WO-2021118929-A1 COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA PTC THERAPEUTICS, INC. (US) 2021-06-17 WO disclosed
WO-2021113492-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRÖDINGER, INC. (US) 2021-06-10 WO disclosed
US-20080293712-A1 Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof WYETH (US) 2008-11-27 US disclosed
WO-2008109613-A1 BENZO[C][2,7]NAPHTHYRIDINE DERIVATIVES, AND THEIR USE AS KINASE INHIBITORS WYETH (US) 2008-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220135586-A1 THIOENO[3,2-B] PYRIDIN-7-AMINE COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA SF3B5, SF3B2, SF3B1 MMP13 4854/4885AAK1 3167/4885
US-20230057568-A1 COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA SNRPB2, SYNCRIP, HNRNPUL2 MMP13 4839/4885AAK1 3534/4885
US-20230101747-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME PLK1, DCK, CSNK1A1 MMP13 2481/4885AAK1 664/4885
US-12384797-B2 Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia SF3B5, SF3B2, SF3B1 MMP13 4854/4885AAK1 3167/4885
US-20080293712-A1 Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof PDPK1, PDK2, PDK3 MMP13 4229/4885AAK1 219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.